Skip to content

FENNEC PHARMACEUTICALS INC.: 10-Q filed 2014-05-15

What FENNEC PHARMACEUTICALS INC. reported in its quarterly report filed 2014-05-15 (fiscal Q1 2014): 22 published measures, 93 facts as tagged in accession 0001144204-14-031132.

This filing

Form
10-Q (quarterly report)
Filed
2014-05-15
Fiscal period
fiscal Q1 2014
Accession
0001144204-14-031132 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All FENNEC PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-311,395,000USD
At 2013-12-311,752,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-315,729,000USD
At 2013-12-313,207,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-31-4,334,000USD
At 2013-12-31-1,455,000USD
At 2012-12-31-4,957,000USD
At 2011-12-31-120,000USD
At 2010-12-31-4,926,000USD
At 2009-12-31406,000USD
At 2008-12-313,053,000USD
At 2007-12-3114,148,000USD
At 2006-12-311,268,000USD
At 2005-12-3111,077,000USD
At 2004-12-3116,654,000USD
At 2004-06-3020,454,000USD
At 2003-06-30698,000USD
At 2002-06-306,071,000USD
At 2001-06-309,792,000USD
At 2000-06-3047,000USD
At 1999-06-30242,000USD
At 1998-06-30-435,000USD
At 1997-06-30-37,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-03-311,338,000USD
At 2013-12-311,663,000USD
At 2013-03-311,896,000USD
At 2012-12-312,303,000USD
At 1996-09-020USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-3,194,000USD90
1996-09-03 to 2014-03-31-110,483,000USD6419
2013-01-01 to 2013-12-311,845,000USD365
2013-01-01 to 2013-03-31-4,108,000USD90
2012-01-01 to 2012-12-31-5,163,000USD366
2011-01-01 to 2011-12-314,685,000USD365
2010-01-01 to 2010-12-31-7,824,000USD365
2009-01-01 to 2009-12-31-3,012,000USD365
2008-01-01 to 2008-12-31-13,600,000USD366
2007-01-01 to 2007-12-31-13,357,000USD365
2006-01-01 to 2006-12-31-16,440,000USD365
2005-01-01 to 2005-12-31-13,871,000USD365
2004-07-01 to 2004-12-31-6,594,000USD184
2003-07-01 to 2004-06-30-6,872,000USD366
2002-07-01 to 2003-06-30-17,795,000USD365
2001-07-01 to 2002-06-30-3,732,000USD365
2000-07-01 to 2001-06-30-2,524,000USD365
1999-07-01 to 2000-06-30-1,605,000USD366
1998-07-01 to 1999-06-30-958,000USD365
1997-07-01 to 1998-06-30-398,000USD365
1996-09-03 to 1997-06-30-37,000USD301

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-378,000USD90
1996-09-03 to 2014-03-31-87,625,000USD6419
2013-01-01 to 2013-03-31-407,000USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
1996-09-03 to 2014-03-311,440,000USD6419
2013-01-01 to 2013-03-310USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
1996-09-03 to 2014-03-310USD6419
2013-01-01 to 2013-03-310USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2014-01-01 to 2014-03-3153,000USD90
1996-09-03 to 2014-03-3190,068,000USD6419
2013-01-01 to 2013-03-310USD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
1996-09-03 to 2014-03-31-1,483,000USD6419
2013-01-01 to 2013-03-310USD90

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-01-01 to 2014-03-3129,308,000shares90
2013-01-01 to 2013-03-3125,158,000shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-01-01 to 2014-03-3129,308,000shares90
2013-01-01 to 2013-03-3125,158,000shares90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-01-01 to 2014-03-31133,000USD90
1996-09-03 to 2014-03-3110,464,000USD6419
2013-01-01 to 2013-03-310USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-537,000USD90
1996-09-03 to 2014-03-31-116,713,000USD6419
2013-01-01 to 2013-03-31-537,000USD90

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-01-01 to 2014-03-310USD90
1996-09-03 to 2014-03-3119,000USD6419
2013-01-01 to 2013-03-310USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-315,729,000USD
At 2013-12-313,207,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-31154,000USD
At 2013-12-31212,000USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-3129,308,000shares
At 2013-12-3129,158,000shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-03-311,243,000USD
At 2013-12-311,243,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-3157,000USD
At 2013-12-31132,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31505,000USD90
1996-09-03 to 2014-03-3133,933,000USD6419
2013-01-01 to 2013-03-31359,000USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-2,657,000USD90
1996-09-03 to 2014-03-316,230,000USD6419
2013-01-01 to 2013-03-31-3,571,000USD90

Inspect the source

Entity
FENNEC PHARMACEUTICALS INC. / CIK 0001211583
Captured
2026-09-19T11:17:02.352Z
SEC response SHA-256
f5de26e280e9814def3db187bfe6961cb26c6e601a5f986375859c81818e8ab8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001211583.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))